Page 28 - GALENIKA MEDICAL JOURNAL

Abstract

Familial Hypercholesterolemia (FH) is a metabolic disorder that is inherited in an autosomal dominant manner and is
characterized by elevated cholesterol levels and the development of premature atherosclerotic cardiovascular disease
(ASCVD). The prevalence of heterozygous FH is 1 in 250-500 individuals, while the prevalence of homozygous FH is 1 in
a million. The molecular basis of this condition involves mutations in the genes encoding the LDL receptor (Low-Density
Lipoprotein Receptor, LDLR), Apolipoprotein B (ApoB), or Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) enzyme.
In patients with FH, laboratory analyses are dominated by elevated levels of low-density lipoprotein cholesterol (LDL-C)
above the 95th percentile for age and gender, with most commonly normal values of high-density lipoprotein cholesterol
(HDL-C) in very low-density lipoprotein cholesterol (VLDL-C), and triglycerides. The gold standard for diagnosing FH is
genetic analysis and mutation detection, but it is often inaccessible due to economic reasons. Today, the diagnosis is
made by applying a scoring system within well-validated questionnaires, which assess the probability of FH based on the
simultaneous analysis of personal and family history, clinical findings of tendon xanthomas or corneal arcus, as well as
biochemical analysis of the lipid profile. Despite clear diagnostic recommendations for FH, there is an extremely low rate
of diagnosis of these patients, even in developed healthcare systems, as well as a low rate of treatment. A large number
of unrecognized FH patients, along with a significantly increased risk of cardiovascular diseases in untreated young FH
patients, have prompted global efforts to diagnose the disease earlier and reduce complications through appropriate
treatment. Cascade screening in the detection of new patients involves analyzing the relatives, first-, second-, and
third-degree, of patients with known FH (index case, proband). Upon identifying a new case, that individual becomes
the new proband, and their relatives are analyzed in subsequent cascades. There are three basic models of cascade
screening: clinical, genetic, and hybrid models. Currently, selective clinical cascade screening is most commonly applied.
Selective cascade screening detects the disease in individuals at high risk of its manifestation. The expert consensus
panel recommends a hybrid model, where genetic testing is performed in all patients with definite or probable FH, and
in cascade screening, both cholesterol levels and genetic analysis are continued in their high-risk relatives. Adequate
detection of FH patients and timely treatment significantly reduce their cardiovascular morbidity and mortality, justifying
the implementation of cascade screening. Conducting screening through routine clinical practice does not yield satisfactory
results. Therefore, it is necessary to organize a screening program at the national level, including the establishment of
lipidology centers and the provision of genetic screening and genetic counseling services.

Keywords: Familial hypercholesterolemia, dyslipidemia, cascade screening, genetic testing, primary prevention

Literatura 8. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig
EH, et al. Diagnosing heterozygous familial hypercholesterolemia using
new practical criteria validated by molecular genetics. Am J Cardiol.
1. Authors/Task Force Members; ESC Committee for Practice Guidelines 1993 Jul 15;72(2):171-6.
(CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for 9. Santos RD, Frauches TS, Chacra AP. Cascade Screening in Familial
the management of dyslipidaemias: Lipid modification to reduce Hypercholesterolemia: Advancing Forward. J Atheroscler Thromb.
cardiovascular risk. Atherosclerosis. 2019 Nov;290:140-205. 2015;22(9):869-80.
2. de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, 10. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L,
Sheldrick RC. Prevalence of Familial Hypercholesterolemia in the 1999 Descamps OS, et al: European Atherosclerosis Society Consensus Panel.
to 2012 United States National Health and Nutrition Examination Familial hypercholesterolaemia is underdiagnosed and undertreated
Surveys (NHANES). Circulation. 2016 Mar 15;133(11):1067-72. in the general population: guidance for clinicians to prevent coronary
3. Varret M, Abifadel M, Rabès JP, Boileau C. Genetic heterogeneity heart disease: consensus statement of the European Atherosclerosis
of autosomal dominant hypercholesterolemia. Clin Genet. 2008 Society. Eur Heart J. 2013 Dec;34(45):3478-90a.
Jan;73(1):1-13. 11. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial
4. Paquette M, Chong M, Thériault S, Dufour R, Paré G, Baass A. hypercholestero- lemia in the danish general population: prevalence,
Polygenic risk score predicts prevalence of cardiovascular disease in coronary artery disease, and cholesterol- lowering medication. J Clin
patients with familial hypercholesterolemia. J Clin Lipidol. 2017 May- Endocrinol Metab. 2012 Nov;97(11):3956-64.
Jun;11(3):725-732.e5. 12. Lázaro P, Pérez de Isla L, Watts GF, Alonso R, Norman R, Muñiz O, et
5. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: al. Cost- effectiveness of a cascade screening program for the early
new insights in pathogenesis and treatment. J Clin Invest. 2003 detection of familial hypercholesterolemia. J Clin Lipidol. 2017 Jan-
Jun;111(12):1795-803. Feb;11(1):260-71.
6. Fouchier SW, Defesche JC, Umans-Eckenhausen MW, Kastelein JP. The 13. Louter L, Defesche J, Roeters van Lennep J. Cascade screening for
molecular basis of familial hypercholesterolemia in The Netherlands. familial hypercholesterolemia: Practical consequences. Atheroscler
Hum Genet. 2001 Dec;109(6):602-15. Suppl. 2017;30:77-85.
7. Heath KE, Humphries SE, Middleton-Price H, Boxer M. A 14. Singh S, Bittner V. Familial hypercholesterolemia-epidemiology,
molecular genetic service for diagnosing individuals with familial diagnosis, and screening. Curr Atheroscler Rep. 2015;17(2):482.
hypercholesterolaemia (FH) in the United Kingdom. Eur J Hum Genet. 15. Groselj U, Kovac J, Sustar U, Mlinaric M, Fras Z, Podkrajsek KT, et al.
2001 Apr;9(4):244-52.

26 DOI: 10.5937/Galmed2306021R